We've Got You Covered
COVID-19 & COVID LONG HAUL SYNDROME
Dr. Wagshul is part of the FLCCC Alliance. Along with nine other leading and concerned physicians, they formed a working group devoted to creating a treatment protocol against COVID-19. Many have sought Dr. Wagshul's medical council and advice as they navigate Covid-19 and LHCS.
Clinical signs and symptoms can be grouped in the following clusters.
Shortness of breath, congestion, persistent cough, etc.
Postural tachycardia syndrome (POTs), abnormal sweating.
myalgias, fatigue, weakness, joint pains, inability to exercise, post-exertional malaise, inability to perform normal activities of daily life (ADL’s).
Brain fog, malaise, tiredness, headaches, migraines, depression, inability to focus/concentrate, altered cognition, insomnia, vertigo, panic attacks, tinnitus, anosmia, phantom smells, etc.
Palpitations, arrhythmias, Raynaud-like syndrome, hypo- tension, and tachycardia on exertion.
Anorexia, diarrhea, bloating, vomiting, nausea, etc.
Itching, rashes, dermatographia 8. mucus membranes: running nose, sneezing, burning, and itchy eyes.
WHAT PATIENTS ARE SAYING
“Thank you for taking the time with me and my daughter. We both learned so much all of which validated the decision I was making about taking Ivermectin as a preventative medication. You imparted so much wisdom and information we CAN NOT begin to thank you enough. ”
Maggee C., Ripley, OH
The Long Haul Covid 19 Syndrome (LHCS) is an often debilitating syndrome characterized by a multitude of symptoms such as prolonged malaise, headaches, generalized fatigue, sleep difficulties, smell disorders, decreased appetite, painful joints, dyspnea, chest pain, and cognitive dysfunction. The incidence of symptoms after COVID-19 varies from as low as 10% to as high as 80%. LCHS is not only seen after the COVID-19 infection but it is being observed in some people that have received vaccines (likely due to monocyte activation by the spike protein from the vaccine). A puzzling feature of the LHCS syndrome is that it is not predicted by initial disease severity; post-COVID-19 frequently affects mild-to-moderate cases and younger adults that did not require respiratory support or intensive care.
The symptom set of LHCS in the majority of cases is very similar to the chronic inflammatory response syndrome (CIRS)/myalgic/encephalomyelitis/chronic fatigue syndrome/, although, in LHCS, symptoms tend to improve slowly in the majority of cases. Furthermore, the similarity between the mast cell activation syndrome and LHCS has been observed, and many consider post-COVID-19 to be a variant of the mast cell activation syndrome. LHCS is highly heterogenous and likely results from a variety of pathogenetic mechanisms. Furthermore, it is likely that delayed treatment (with ivermectin) in the early symptomatic phase will result in a high viral load, which increases the risk and severity of LHCS.
Although numerous reports describe the epidemiology and clinical features of LHCS, studies evaluating treatment options are glaringly sparse. Indeed, the NICE guideline for managing the long-term effects of COVIS-19 provides no specific pharmacologic treatment recommendations.